The Relative Oral Bioavailability of a Tablet Formulation vs a Solutionof PLN-74809 in Healthy Participants

Pliant Therapeutics, Inc.0 个研究点目标入组 24 人开始时间: 2020年5月15日最近更新: 2020年5月25日

适应症

试验速览

暂无简介。

•1. 18 to 55 years
•2. Good general health, with no significant medical history and no clinically significant
•abnormalities at screening and/or before administration of the initial dose of study drug.
•3. Body weight greater than or equal to 50 kg at the Screening Visit.
•4. Body mass index (BMI) between 18 and 30 kg/m2, inclusive.
•5. Participants must use adequate contraception for male and female participants of childbearing potential.
•6. Understand the study procedures and agrees to participate in the study by giving written informed consent.

•- History of clinically significant abnormalities or diseases.
•- Pregnant or lactating females.
•- Positive test for hepatitis C antibody (HCVAb), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody at Screening.
•- Positive toxicology screening panel
•- History of substance abuse or dependency or history of recreational drug use.
•- Alcohol consumption greater than 14 drinks per week for males (7 for females).
•- Smokers or ‘vapers’ (cigarette or other modalities).
•- Unable to refrain from or anticipates the use of any medications, including prescription and non-prescription drugs and herbal supplements.
•- Unlikely to comply with the study protocol or, in the opinion of the Investigator, would not be a suitable candidate for participation in the study.
•- Have participated in any other investigational drug trial within 30 days or 5 half-lives (whichever is longer) of dosing in the present study.

发起方